WallStreetZenWallStreetZen

NASDAQ: VTRS
Viatris Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

VTRS past earnings growth

How has VTRS's earnings growth performed historically?
Company
142.86%
Industry
62.68%
Market
36.22%
VTRS's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
VTRS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
VTRS's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

VTRS past revenue growth

How has VTRS's revenue growth performed historically?
Company
-9.22%
Industry
10.68%
Market
13.73%
VTRS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VTRS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VTRS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VTRS earnings and revenue history

Current Revenue
$15.6B
Current Earnings
$1.9B
Current Profit Margin
11.9%
VTRS's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

VTRS Return on Equity

Current Company
9%
Current Industry
11.8%
Current Market
22.1%
VTRS's Return on Equity (9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VTRS announces earnings.

VTRS Return on Assets

Current Company
3.8%
Current Industry
3.7%
VTRS is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VTRS Return on Capital Employed

Current Company
7.45%
Current Industry
6.8%
VTRS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VTRS vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VTRS$15.60B$6.13B$1.85B+5.89%+11.95%
TEVA$15.02B$249.00M-$2.23B-5.80%N/A
RDY$2.99B$904.61M$547.73M+6.52%N/A
NBIX$1.67B$257.30M$176.40M+38.93%+73.92%
CTLT$4.50B$590.00M$21.00M+13.42%-25.13%
View Top Pharmaceutical Stocks

VTRS earnings dates

Next earnings date
Nov 6, 2023

Viatris Earnings & Revenue FAQ

What were VTRS's earnings last quarter?

On Invalid Date, Viatris (NASDAQ: VTRS) reported Q2 2023 earnings per share (EPS) of $0.22, up 15.38% year over year. Total Viatris earnings for the quarter were $264.00 million. In the same quarter last year, Viatris's earnings per share (EPS) was $0.26.

If you're new to stock investing, here's how to buy Viatris stock.

What was VTRS's earnings growth in the past year?

As of Q3 2023, Viatris's earnings has grown 142.86% year over year. This is 80.18 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 62.68%. Viatris's earnings in the past year totalled $1.85 billion.

What is VTRS's earnings date?

Viatris's earnings date is Invalid Date. Add VTRS to your watchlist to be reminded of VTRS's next earnings announcement.

What was VTRS's revenue last quarter?

On Invalid Date, Viatris (NASDAQ: VTRS) reported Q2 2023 revenue of $3.92 billion up 4.81% year over year. In the same quarter last year, Viatris's revenue was $4.12 billion.

What was VTRS's revenue growth in the past year?

As of Q3 2023, Viatris's revenue has grown -9.22% year over year. This is 19.9 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.68%. Viatris's revenue in the past year totalled $15.60 billion.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.